患者导向湿疹测量(POEM)作为临床试验症状核心工具的HOME声明
HOME initiative通过系统综述和共识会议,为特应性湿疹试验的症状核心域选择测量工具。建议未来所有特应性湿疹临床试验采用POEM测量症状,其他工具可附加使用。
要点
- HOME推荐POEM作为特应性湿疹试验症状核心域的核心测量工具。
- 其他感兴趣的工具可在POEM基础上附加使用。
核心结论
- POEM被推荐为未来所有特应性湿疹临床试验中测量症状核心域的核心工具。
研究设计与样本
- HOME倡议通过路线图开展两项系统综述,筛选出三种具有充分效度、信度和可行性证据的工具。
- 在第四次国际HOME会议上,各利益相关方对核心工具选择进行共识投票。
关键数值与推荐
- HOME核心结局集(COS)定义四个核心域:临床体征、症状、生活质量和长期控制。
- 系统综述筛选出三种工具具备充分效度、信度和可行性证据以供最终COS考虑。
临床怎么用
- 未来特应性湿疹临床试验应使用POEM测量症状核心域。
- 其他感兴趣的症状测量工具可在POEM之外附加使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control. OBJECTIVES: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. METHODS: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. RESULTS: At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed). CONCLUSIONS: All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.
引用
- Spuls PI, Gerbens LAA, Simpson E, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017. PMID: 27858989. doi:10.1111/bjd.15179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。